

## Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (WP4), with a focus on the period from January to March 2022.

In Q1 2022, the recruitment rate stagnated and the scanning rate decreased compared to Q4 2021. This is as expected as the study is now in the final months where more and more sites have now consented/scanned (almost) all their participants. In addition, there have been other factors affecting the recruitment and scanning rates such as availability of the tracer which will be discussed further in the report. The recruiting sites have not been directly affected by COVID-19 during this quarter and VUMC has welcomed some participants of the AMYPAD DPMS cohort into the study.

In total, at the end of Q1 2022, AMYPAD PNHS had 1259 participants consented of which 1113 have received a baseline PET scan and 216 the FU PET scan within AMYPAD PNHS. Moving forward, in Q2 2022 the recruitment and scanning rate will decrease as we are approaching the end of the study and all sites will be done with the recruitment in April and with the scanning depending on the site between the end of April and end of June.

**For more information:** [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

